Drilldown: Medicines
Medicines > classes 
:
Anticonvulsant or
Antidepressant or
[[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]]
:
Anticonvulsant or
Antidepressant or
[[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]] Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Brivaracetam (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Clomipramine (1) ·
Clozapine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fosphenytoin (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Lacosamide (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Perampanel (1) ·
Phenelzine (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Rufinamide (1) ·
Sertraline (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
None (1) ·
Anafranil (1) ·
Aptiom (1) ·
Aurorix (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Edronax (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fetzima (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Ludiomil (1) ·
Luminal (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Onfi (1) ·
Parnate (1) ·
Sabril (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vimpat (1) ·
Vivactil (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zoloft (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin releaser; sigma-1 agonist (1) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00000049-QINU`"' (1)
uses:
starting dose:
None (37) ·
12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1) ·
25 mg (1)
preparations:
None (37) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1)
fda max:
routes:
onset:
None (36) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)
duration:
halflife:
bioavailability:
pregnancy:
legal:
Showing below up to 39 results in range #1 to #39.